Literature DB >> 1837020

The Yersinia pseudotuberculosis invasin protein and human fibronectin bind to mutually exclusive sites on the alpha 5 beta 1 integrin receptor.

G T Van Nhieu1, R R Isberg.   

Abstract

The Yersinia pseudotuberculosis invasin protein promotes bacterial penetration into mammalian cells by binding to several beta 1 chain integrins. We show here that proteins containing the cell-binding domain of invasin bind to the fibronectin receptor alpha 5 beta 1 isolated from human placenta and immobilized on a filter membrane. Two forms of the receptor, each having a molecular weight of about 290,000, were immunodepleted by monoclonal antibodies specific for the beta 1 subunit or the alpha 5 beta 1 heterodimer. The binding of invasin to the receptor immobolized on the filter, or to whole JAR cells, reaches saturation after 90 min and has an apparent dissociation constant (Kd) of 5.0 x 10(-9) M. Invasin binding to alpha 5 beta 1 is inhibited by the 120-kDa chymotryptic fragment of fibronectin in a competitive manner with an inhibition constant (Ki) of 7.5 x 10(-7) M. Furthermore, invasin-receptor binding is also inhibited by the hexapeptide GRGDSP, and monoclonal antibodies that block cell attachment to invasin-coated surfaces also block cell attachment to fibronectin-coated surfaces. These results indicate that invasin and fibronectin bind to the same, or closely located sites on alpha 5 beta 1, although invasin binds with a much higher affinity than does fibronectin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837020

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart.

Authors:  M L Valencik; J A McDonald
Journal:  Transgenic Res       Date:  2001-06       Impact factor: 2.788

Review 2.  Host-pathogen interactions: the seduction of molecular cross talk.

Authors:  P Sansonetti
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  The integrin-binding domain of invasin is sufficient to allow bacterial entry into mammalian cells.

Authors:  S Rankin; R R Isberg; J M Leong
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

4.  Rv2468c, a novel Mycobacterium tuberculosis protein that costimulates human CD4+ T cells through VLA-5.

Authors:  Qing Li; Xuedong Ding; Jeremy J Thomas; Clifford V Harding; Nicole D Pecora; Assem G Ziady; Samuel Shank; W Henry Boom; Christina L Lancioni; Roxana E Rojas
Journal:  J Leukoc Biol       Date:  2011-12-07       Impact factor: 4.962

5.  A small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation.

Authors:  Nicole Tegtmeyer; Roland Hartig; Robin M Delahay; Manfred Rohde; Sabine Brandt; Jens Conradi; Seiichiro Takahashi; Adam J Smolka; Norbert Sewald; Steffen Backert
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

Review 6.  The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual.

Authors:  A T Florence
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

7.  Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles.

Authors:  N Hussain; A T Florence
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

8.  Molecular characterization of a carboxy-terminal eukaryotic-cell-binding domain of intimin from enteropathogenic Escherichia coli.

Authors:  G Frankel; D C Candy; E Fabiani; J Adu-Bobie; S Gil; M Novakova; A D Phillips; G Dougan
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  Pathogenesis of defined invasion mutants of Yersinia enterocolitica in a BALB/c mouse model of infection.

Authors:  J C Pepe; M R Wachtel; E Wagar; V L Miller
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Immunologic recognition of a 25-amino acid repeat arrayed in tandem on a major antigen of Blastomyces dermatitidis.

Authors:  B S Klein; L H Hogan; J M Jones
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.